Targeting KRAS in Cancer Therapy: Beyond Inhibitors

Targeting KRAS in Cancer Therapy: Beyond Inhibitors

Saved in:

Bibliographic Details
Main Authors:	Chunhui Chen, Zhiqiang Peng, Lingqiang Zhang
Format:	Article
Language:	English
Published:	Wiley 2025-07-01
Series:	MedComm
Online Access:	https://doi.org/10.1002/mco2.70267
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
by: Zhang Yang, et al.
Published: (2021-08-01)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)

Targeting KRAS: from metabolic regulation to cancer treatment
by: Yanyan Shi, et al.
Published: (2025-01-01)

KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy
by: Xuanhua Yang, et al.
Published: (2025-07-01)

Computational screening of phytochemicals targeting mutant KRAS in colorectal cancer
by: Muskan Arooj, et al.
Published: (2025-08-01)

The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
by: Qinglong Ma, et al.
Published: (2025-01-01)

Berbamine as potential STING inhibitor For KRAS-mutant non-small cell lung cancer
by: Haoxin Yan, et al.
Published: (2025-06-01)

Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors
by: Giorgia Anastasio, et al.
Published: (2025-02-01)

The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer
by: Angela Abdollahi, et al.
Published: (2025-01-01)

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy
by: Anastasia Goloudina, et al.
Published: (2025-07-01)

Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy
by: Li Peng, et al.
Published: (2025-08-01)

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells
by: Lei Jiang, et al.
Published: (2019-12-01)

High-dose vitamin C as a targeted treatment for KRAS-driven cancers?
by: Elisabeth Mack, et al.
Published: (2025-09-01)

Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy
by: İsa Taş, et al.
Published: (2025-04-01)

Quantum biological convergence: quantum computing accelerates KRAS inhibitor design
by: Taeho Kwon, et al.
Published: (2025-05-01)

KRAS-mutated non-small cell lung cancer: new therapy strategies
by: K. K. Laktionov, et al.
Published: (2024-05-01)

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer
by: A. N. Toropovskiy, et al.
Published: (2022-11-01)

Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development
by: Han Koo, et al.
Published: (2025-01-01)

A Minireview on BET Inhibitors: Beyond Bromodomain Targeting
by: Mikhail S. Iudin, et al.
Published: (2025-03-01)

Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
by: Hyungkyung Shin, et al.
Published: (2025-05-01)

Role and mechanism of action of nuclear receptor coactivator 4 in the development of acquired resis-tance to targeted inhibitors in pancreatic cancer with KRAS G12C mutation
by: CHANG Hao, WANG Ya'nan, LIU Shihai, WANG Jing
Published: (2025-08-01)

Marijan Kraš
by: Andrea Toljan, et al.
Published: (2023-11-01)

Mutational profile of KRAS-positive colorectal cancer
by: E. N. Telysheva, et al.
Published: (2022-03-01)

Epilepsy therapy beyond neurons: Unveiling astrocytes as cellular targets
by: Yuncan Chen, et al.
Published: (2026-01-01)

Study on the mechanism of KRAS R68G secondary mutation-induced resistance to KRASG12D-targeted inhibitor MRTX1133
by: WANG Gaoming, et al.
Published: (2025-06-01)

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
by: Dan-Yun Ruan, et al.
Published: (2025-06-01)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
by: Sara Costa-Cabral, et al.
Published: (2016-01-01)

Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas.
by: Saleh Al-Ghamdi, et al.
Published: (2011-01-01)

Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review
by: Fan Zhang, et al.
Published: (2025-04-01)

ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer
by: Chiara Pozzato, et al.
Published: (2024-09-01)

Metabolic reprogramming and therapeutic targeting in non-small cell lung cancer: emerging insights beyond the Warburg effect
by: Hong Cai, et al.
Published: (2025-05-01)

Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells
by: Yingying Wang, et al.
Published: (2024-12-01)

Josephin Domain Containing 2 (JOSD2) inhibition as Pan-KRAS-mutation-targeting strategy for colorectal cancer
by: Tao Yuan, et al.
Published: (2025-04-01)

Efficacy of CRISPR-Cas9 gene editing for targeting KRAS mutations in pancreatic cancer: a systematic review
by: Hashim Talib Hashim, et al.
Published: (2025-04-01)

Combination of AURKA inhibitor and MEK inhibitor strongly enhances G1 arrest and induces synergistic antitumor effect on KRAS or BRAF mutant colon cancer cells
by: Masashi Sato, et al.
Published: (2025-09-01)

Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer
by: Xinyue YANG, et al.
Published: (2025-05-01)

Optimizing blood-brain barrier permeability in KRAS inhibitors: A structure-constrained molecular generation approach
by: Xia Sheng, et al.
Published: (2025-08-01)

Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
by: Nawaz Khan, et al.
Published: (2025-07-01)

Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
by: Shenao Fu, et al.
Published: (2025-07-01)

Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer
by: Ibha Singh, et al.
Published: (2025-07-01)